Treating MMN: Standard Options and Important Warnings

Back to Home

Once you have a confirmed diagnosis of Multifocal Motor Neuropathy (MMN), the focus shifts to a single, critical goal: calming your immune system to restore and protect your muscle strength. Unlike many other autoimmune conditions, MMN requires a very specific approach.

The Gold Standard: IVIg

The first-line treatment for MMN is Intravenous Immunoglobulin (IVIg) ^[1][2]. This treatment involves infusing concentrated antibodies collected from thousands of healthy donors directly into your vein.

Rather than just hunting down specific “bad” antibodies, IVIg works by broadly modulating (calming) your immune system and stopping the complement system from attacking your nerves. Because of this broad action, IVIg is highly effective regardless of whether you tested positive or negative for anti-GM1 antibodies ^[1].

Most patients notice an improvement in strength within days or weeks of their first loading dose (a larger initial dose given over several days to quickly build up antibody levels). However, IVIg is not a cure; it is a lifelong maintenance therapy that typically requires regular infusions every 2 to 5 weeks ^[2].

Navigating Side Effects and Logistics

IVIg is a time-consuming and expensive therapy. You may need to work closely with your clinic to navigate insurance approvals or find patient assistance programs. Because you will be on this therapy long-term, it is vital to understand the side effects:

• Common Side Effects: Headaches, fatigue, chills, and flu-like symptoms are common during or shortly after the infusion. Your care team can help manage these by slowing the infusion rate and providing “premedications” before you start, such as hydration (IV fluids), antihistamines (like Benadryl), and acetaminophen (Tylenol) ^[2].
• Severe Risks: Though rare, IVIg can cause serious complications, including blood clots (thrombosis), kidney impairment, or a severe inflammatory headache called aseptic meningitis. If you experience severe, persistent headaches, neck stiffness, chest pain, or shortness of breath, contact your doctor immediately.

Smooth and Steady: The Role of SCIg

Many patients experience “wearing-off” periods, where their strength begins to dip in the final days before their next scheduled IVIg infusion ^[3]. In these cases, Subcutaneous Immunoglobulin (SCIg) is an excellent maintenance alternative ^[4].

With SCIg, the medication is infused into the fatty tissue under the skin using small needles, usually once or twice a week.

• Home Treatment: SCIg can be self-administered by the patient at home, offering more flexibility and independence ^[5]. Transitioning to SCIg requires training, and your doctor will need to carefully adjust your dose to ensure you maintain your strength ^[3].
• Fewer Fluctuations: Because it is given more frequently, SCIg keeps the levels of immunoglobulin in your blood more stable, which can eliminate the “rollercoaster” effect of IVIg ^[3][6].
• Safety: SCIg is generally well-tolerated and often has fewer systemic side effects (like massive headaches) compared to large IVIg doses ^[3].

CRITICAL: What to Avoid

One of the most important things for an MMN patient to know is what not to take. MMN is unique among immune-mediated neuropathies because certain common treatments do not work and can be harmful:

• No Corticosteroids: Medications like prednisone are generally ineffective for MMN ^[2]. In some cases, steroids have actually worsened muscle weakness in MMN patients ^[7]. This is a key difference from conditions like CIDP.
• No Plasma Exchange: While “cleaning the blood” (plasmapheresis) helps in other conditions, it typically provides no benefit for MMN and is not recommended as a standard treatment ^[2][7].

When Treatment Response Fades

For some patients, the initial “boost” from IVIg may begin to diminish over several years ^[8]. If this happens, your neurology team has strategies:

1. Dose Individualization: Your doctor may increase the frequency or the amount of IVIg to find your specific “sweet spot” ^[9].
2. Rituximab: In select cases where immunoglobulin is no longer enough, doctors may consider rituximab, a medication that targets the B-cells responsible for producing antibodies ^[10][7].